Showing results (1-10 of 364) with videos related to
Sort By:
Pageof 37
Oncoimmunology|April 9, 2016
Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancerSumanta K Pal, Marcin KortylewskiCancer Discovery|December 4, 2019
Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway InhibitionVivek Subbiah, Sumanta K PalNature Reviews. Clinical Oncology|July 30, 2014
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancerSumanta K Pal, Oliver SartorNature Reviews. Clinical Oncology|November 15, 2012
Abiraterone and its place in the treatment of metastatic CRPCOliver Sartor, Sumanta K PalOncoimmunology|October 24, 2014
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapyMarcin Kortylewski, Sumanta K PalCancer Treatment Reviews|February 26, 2013
Differentiating mTOR inhibitors in renal cell carcinomaSumanta K Pal, David I QuinnThe Oncologist|June 28, 2014
Adjuvant therapy for renal cell carcinoma: past, present, and futureSumanta K Pal, Naomi B HaasThe Urologic Clinics of North America|October 23, 2012
Management of docetaxel failures in metastatic castrate-resistant prostate cancerSumanta K Pal, Brian Lewis, Oliver SartorAsian Journal of Andrology|April 10, 2014
Radium-223 in metastatic castration resistant prostate cancerWinston Vuong, Oliver Sartor, Sumanta K PalCancer Discovery|September 6, 2023
FGFR Inhibition: Understanding and Overcoming ResistanceAbhishek Tripathi, Daneng Li, Sumanta K PalPageof 37